NDAORALTABLET
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
UPTRAVI (selexipag) by Johnson & Johnson is prostacyclin receptor agonists [moa]. First approved in 2015.
Drug data last refreshed 8h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UPTRAVI (selexipag) is an oral prostacyclin receptor agonist approved in 2015 for pulmonary arterial hypertension (PAH). It works by mimicking prostacyclin, a naturally occurring vasodilator that reduces pulmonary vascular resistance and improves exercise capacity in PAH patients. This is the only selective prostacyclin receptor (IP) agonist available in oral form.
$0.758BPart D
Peak10.7 years to LOEUPTRAVI is in peak lifecycle stage with substantial Medicare spending, indicating a mature, stable commercial franchise with established market presence and stable team sizing.
Mechanism of Action
Prostacyclin Receptor Agonists
Pharmacologic Class:
Prostacyclin Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Started Oct 2020
20 enrolled
Pulmonary HypertensionSchistosomiasis
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Started Oct 2020
372 enrolled
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Started May 2017
0Pulmonary Arterial Hypertension
Why This Matters for Your Career
Worked on UPTRAVI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.